CClinicalTrials.gg
Sign In
CompletedNCT02174172Updated May 12, 2020

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of Atezolizumab and Bevacizumab in Solid Cancers, sponsored by Hoffmann-La Roche. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-12.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
158
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This global, multicenter, open-label study will evaluate the safety and tolerability of atezolizumab in combination with other immune-modulating therapies in the treatment of selected advanced or metastatic malignancies. The atezolizumab plus ipilimumab arm (Arm A) will focus primarily on participants with advanced or metastatic non-small cell lung cancer (NSCLC). The atezolizumab plus interferon alfa-2b arm (Arm B), plus pegylated interferon alfa-2a (PEG-interferon alfa-2a, Arm C), and atezolizumab plus PEG-interferon Alfa-2a plus bevacizumab (Arm D) will enroll participants with advanced or metastatic renal cell carcinoma (RCC), metastatic NSCLC and melanoma. The atezolizumab plus obinutuzumab) (Arm E) will enroll participants with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Atezolizumab will be administered as intravenous (IV) infusion every 3 weeks (q3w).

02

Conditions studied

  • Solid Cancers
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,061 studies on the registry; 85 are open to participants now.

Of its 319 completed or terminated interventional studies of FDA-regulated products, 239 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Histologically or cytologically documented locally advanced or metastatic solid tumors meeting the following study drug-specific criteria:
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Life expectancy greater than or equal to (>/=) 12 weeks
  • Measurable disease, as defined by RECIST v1.1
  • Adequate hematologic and end organ function as confirmed by laboratory results within 14 days prior to the first study treatment

Inclusion criteria specific to Arm A: Atezolizumab+ Ipilimumab

  • Escalation stage: NSCLC participants
  • Mandatory biopsy cohort: NSCLC or melanoma atezolizumab
  • Prior atezolizumab-treated cohort: participants with NSCLC or melanoma previously treated with atezolizumab

Inclusion criteria specific to Arm B: Atezolizumab+ Interferon alfa-2b

  • Escalation stage: RCC or melanoma participants
  • Expansion stage: RCC or melanoma participants
  • Mandatory biopsy cohort: RCC or melanoma participants
  • Prior immunotherapy-treated cohort: participants with RCC, NSCLC, or melanoma previously treated with programmed death-ligand 1 (PD-L1)/ Programmed death 1 (PD-1)

Inclusion Criteria Specific to Arm C (Atezolizumab plus PEG-Interferon Alafa-2a):

  • Cohort 1: participants with RCC

Inclusion Criteria Specific to Arm D (Atezolizumab plus PEG-Interferon Alfa-2a +Bevacizumab)

  • Cohort 1: participants with metastatic RCC with no prior line of systemic therapy for metastatic disease
  • Cohorts 2-3: disease progression during or after at least one previous systemic, anti-cancer treatment for locally advanced or metastatic non-squamous solid tumors; participants with sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements must have failed or are intolerant to prior treatment with EGFR or ALK inhibitors; participants with melanoma with actionable BRAF mutations (e.g., V600) must have failed or are intolerant to prior treatment with BRAF inhibitors

Inclusion Criteria Specific to Arm E (Atezolizumab +Obinutuzumab)

  • R/M HNSCC participants with at least one prior line of systemic therapy

Inclusion Criteria Specific to prior Anti-PD-L1/PD-1 Treated Cohorts:

  • No permanent discontinuation of atezolizumab or other immunotherapies due to a treatment-related adverse event
  • Recovery from all immunotherapy-related adverse events to Grade less than or equal to (≤) 1 or baseline at the time of consent

Exclusion Criteria:

General Medical Exclusions:

  • Pregnant and lactating women
  • Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment, with the following exception: (1) hormone-replacement therapy or oral contraceptives; (2) tyrosine kinase inhibitors (TKIs) that have been discontinued greater than (>) 7 days prior to Cycle 1, Day 1, baseline scans must be obtained after discontinuation of prior TKIs
  • Investigational therapy within 28 days prior to initiation of study treatment
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  • Known hypersensitivity or allergy to Chinese hamster ovary cell products or any component of the atezolizumab formulation
  • History of or active autoimmune disease
  • History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, risk of pulmonary toxicity, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Prior allogeneic bone marrow transplantation or prior solid organ transplantation
  • History of human immunodeficiency virus (HIV)
  • Participants with active hepatitis B
  • Participants with active hepatitis C
  • Participants with active tuberculosis
  • Participants with a history of confirmed progressive multifocal leukoencephalopathy
  • Any serious medical condition, physical examination finding, or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study

Cancer-Specific Exclusions:

  • Active or untreated central nervous system (CNS) metastases, as determined by CT or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments
  • Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for >/= 2 weeks prior to screening
  • Leptomeningeal disease
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently); participants with indwelling catheters are allowed.
  • Uncontrolled tumor-related pain
  • Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab
  • History of other malignancy within 2 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, localized prostate cancer treated with curative intent, ductal carcinoma in situ treated surgically with curative intent, or other cancers with a similar outcome

Exclusion Criteria Related to Medications:

  • Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies (Note: Participants enrolled in the prior anti-PD-L1/PD-1 treated cohorts with melanoma may have received prior anti-cytotoxic T-lymphocyte-associated protein 4 treatment or other immunotherapies)
  • Treatment with systemic immunostimulatory agents within four weeks or five half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1
  • Treatment with systemic immunosuppressive medications within 2 weeks prior to Cycle 1, Day 1 (the use of inhaled corticosteroids and mineralocorticoids is allowed)

Exclusion Criteria Specific to Interferon Alpha Therapy (Arms B-D):

  • History of depression, suicidal ideation or behavior, bipolar disorder, or psychosis
  • Hypersensitivity to interferon alpha or any component of the product

Exclusion Criteria Specific to Bevacizumab (Arm D)

  • Inadequately controlled hypertension
  • Prior history of hypertensive crisis or hypertensive encephalopathy
  • Significant vascular disease within 6 months prior to Day 1
  • History of hemoptysis
  • Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
  • History of tracheoesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1
  • Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding
  • Evidence of abdominal free air that is not explained by paracentesis or recent surgical procedure
  • Proteinuria, as demonstrated by urine dipstick or > 1.0 gram of protein in a 24-hour urine collection
  • Metastatic disease that involves major airways or blood vessels, or centrally located mediastinal tumor masses of large volume

Exclusion Criteria Specific Obinutuzumab (Arm E)

  • Hypersensitivity to obinutuzumab
  • Prior treatment with obinutuzumab
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    Arm A: Atezolizumab with Ipilimumab

    Participants will receive atezolizumab along with ipilimumab.

    Drug: Atezolizumab · Drug: Ipilimumab

  • Experimental
    Arm B: Atezolizumab with Interferon alfa-2b

    Participants will receive atezolizumab along with Interferon alfa-2b.

    Drug: Atezolizumab · Drug: Interferon alfa-2b

  • Experimental
    Arm C: Atezolizumab with PEG- interferon alfa-2a

    Participants will receive atezolizumab along with PEG- interferon alfa-2a.

    Drug: Atezolizumab · Drug: PEG-interferon alfa-2a

  • Experimental
    Arm D:Atezolizumab with PEG-interferon alfa-2a and Bevacizumab

    Participants will receive atezolizumab along with PEG- interferon alfa-2a and bevacizumab.

    Drug: Atezolizumab · Drug: Bevacizumab · Drug: PEG-interferon alfa-2a

  • Experimental
    Arm E: Atezolizumab with Obinutuzumab

    Participants will receive atezolizumab along with obinutuzumab or atezolizumab alone.

    Drug: Atezolizumab · Drug: Obinutuzumab

Interventions

  • DrugAtezolizumab

    Participant will receive atezolizumab 600 milligrams (mg) or 1200 mg by IV infusion q3w.

    Also known as: Tecentriq, RO5541267, MPDL3280A

  • DrugBevacizumab

    Participant will receive Bevacizumab 15 milligrams per kilograms (mg/kg) IV infusion q3w.

    Also known as: Avastin®

  • DrugInterferon alfa-2b

    Participants will receive Interferon alfa-2b 3, 5, or 10 million international units subcutaneously every other day for up to 3 doses per week.

  • DrugIpilimumab

    Participants will receive Ipilimumab 1, or 3 mg/kg IV, single dose, or multiple-dose regimen q3w for up to 4 cycles (Cycle = 21 days).

  • DrugObinutuzumab

    Obinutuzumab 1000 milligrams will be administered as pre-treatment on 2 consecutive days (Day -13 and Day -12) prior to treatment start with atezolizumab on Cycle 1, Day 1 (cycle length=21 days). An additional two doses of obinutuzumab will be administered on Days 85 and 86 of study treatment (Cycle 5, Day 1 and Cycle 5, Day 2).

  • DrugPEG-interferon alfa-2a

    Participant will receive PEG-interferon alfa-2a 180 micrograms subcutaneous injection q3w for a total of 6 cycles (Cycle = 21 days).

    Also known as: Pegasys®

06

What researchers measure

Primary outcomes

  1. Recommended Phase II Dose (RP2D) of Atezolizumab When Given in Combination With Ipilimumab and Interferon Alfa-2b

    Time frame: From the first atezolizumab treatment up to 21 days

  2. Percentage of Participants with Adverse Events

    Time frame: From the first atezolizumab treatment up to 4.5 years (yr)

Secondary outcomes

  1. Percentage of Participants with Best Overall Response, as Assessed Using Conventional Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: Screening to progression or death, up to 4.5 yr (assessed at baseline, every 6 weeks for 48 weeks and every 12 weeks thereafter up to treatment completion/early termination [up to 4.5 yr])

  2. Percentage of Participants with Best Overall Response, as Assessed Using Immune Modified RECIST Criteria

    Time frame: Screening to progression or death, up to 4.5 years (assessed at baseline, every 6 weeks for 48 weeks and every 12 weeks thereafter up to treatment completion/early termination [up to 4.5 yr])

  3. Duration of Objective Response

    Time frame: Screening to progression or death, up to 4.5 yr (assessed at baseline, every 6 weeks for 48 weeks and every 12 weeks thereafter up to treatment completion/early termination [up to 4.5 yr])

  4. Overall Survival

    Time frame: Baseline to death (up to 4.5 yr)

  5. Progression-Free Survival

    Time frame: Screening to progression or death, up to 4.5 yr (assessed at baseline, every 6 weeks for 48 weeks and every 12 weeks thereafter up to treatment completion/early termination [up to 4.5 yr])

  6. Percentage of Participants with Objective Response, as Assessed Using Conventional RECIST v1.1

    Time frame: Screening to progression or death, up to 4.5 yr (assessed at Baseline, every 6 weeks for 48 weeks and every 12 weeks thereafter up to treatment completion/early termination [up to 4.5 yr])

  7. Percentage of Participants with Objective Response, as Assessed Using Immune Modified RECIST Criteria

    Time frame: Screening to progression or death, up to 4.5 yr (assessed at Baseline, every 6 weeks for 48 weeks and every 12 weeks thereafter up to treatment completion/early termination [up to 4.5 yr])

  8. Serum Atezolizumab Concentration

    Arm A: Predose (0 hour \[hr\]), 30 minutes (min) post end of infusion on Day 1;Day 8,Day 15 of Cycle (cy) 1;Predose (0 hr) on Day 1 of cy 2,3,4,8; end of treatment/withdrawal;≥ 90 days post last dose (up to 4.5 years \[yr\]). Arm B: Predose (0 hr) on Day 1,30 min post end of infusion on Day 8,Day 15,Day 22 of cy 1;Predose (0 hr) on Day 1 of cy 2,3,4,5,8; end of treatment/withdrawal;≥ 90 days post last dose (up to 4.5 yr). Arms C,D: Predose (0 hr), 30 min post end of infusion on Day 1 cy 1,3;Predose (0 hr) on Day 1 of cy 2,4,8, every 8 cy thereafter up to end of treatment/withdrawal;≥ 90 days post last dose (up to 4.5 yr). Arm E: Predose (0 hr), 30 min post end of infusion on Day 1 cy 1,5;Predose (0 hr) on Day 1 of cy 2,3,4,8, every 8 cy thereafter up to treatment end of treatment/withdrawal;≥ 90 days post last dose (up to 4.5 yr). Cycle length = 21 days (28 days for Arm B, cycle 1)

    Time frame: Baseline up to 4.5 years (detailed timeframe is given in outcome description)

  9. Serum Ipilimumab Concentration

    Predose (0 hr), 30 min post end of infusion on Day 1 of Cy 1,3;Predose on Day 1 of Cy 4; end of treatment/ withdrawal;≥ 90 days post last dose (up to 4.5 yr) Cycle length = 21 days

    Time frame: Baseline up to 4.5 years (detailed timeframe is given in outcome description)

  10. Serum Bevacizumab Concentration

    Predose (0 hr), 30 min post end of infusion on Day 1 of Cy 1,3; end of treatment/ withdrawal;≥ 90 days post last dose (up to 4.5 yr) Cycle length = 21 days

    Time frame: Baseline up to 4.5 years (detailed timeframe is given in outcome description)

  11. Serum Obinutuzumab Concentration

    Predose (0 hr), 30 min post end of infusion on Days -13, -12 and on Day 1 Cy 5; end of treatment/withdrawal;≥90 days post last dose (up to 4.5 yr) Cycle length = 21 days

    Time frame: Baseline up to 4.5 years (detailed outcome given in outcome description)

  12. Anti-Drug Antibody to Atezolizumab

    Detailed timeframe: Arm A: Predose (0 hr) on Day 1 of Cy 1,2,3,4,8; end of treatment/withdrawal;≥ 90 days post last dose (up to 4.5 yr). Arm B: Predose (0 hr) on Day 1 of Cy 1,2,3,4,5,8; end of treatment/withdrawal;≥ 90 days post last dose (up to 4.5 yr). Arms C, D, E: Predose (0 hr) on Day 1 of cy 1,2,3,4,8, thereafter every 8 Cy up to end of treatment/ withdrawal;≥ 90 days post last dose (up to 4.5 yr). Cycle length = 21 days (28 days for Arm B, cycle 1)

    Time frame: Baseline up to 4.5 years (detailed timeframe is given in outcome description)

  13. Anti-Drug Antibody to Ipilimumab

    Pre-dose (0 hr) on Day 1 of Cy 1, 4, end of treatment/ withdrawal;≥ 90 days post last dose (up to 4.5 yr) Cycle length = 21 days

    Time frame: Baseline up to 4.5 years (detailed timeframe is given in outcome description)

  14. Anti-Drug Antibody to Bevacizumab

    Predose (0 hr) on Day 1 of Cy 1, 3; end of treatment/withdrawal;≥ 90 days post last dose (up to 4.5 yr). Cycle length = 21 days

    Time frame: Baseline up to 4.5 years (detailed timeframe is given in outcome description)

  15. Anti-Drug Antibody to Obinutuzumab

    Predose (0 hr) on Days -13 and -12; end of treatment/withdrawal;≥ 90 days post last dose (up to 4.5 yr) Cycle length = 21 days

    Time frame: Baseline up to 4.5 years (detailed timeframe is given in outcome description)

07

Study locations

9 sites
  • HonorHealth Research Institute - Bisgrove
    Scottsdale, Arizona 85258, United States
  • Mayo Clinic- Scottsdale
    Scottsdale, Arizona 85259, United States
  • UCLA
    Los Angeles, California 90095, United States
  • Yale University
    New Haven, Connecticut 06510, United States
  • Mayo Clinic-Jacksonville
    Jacksonville, Florida 32224, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Sarah Cannon Research Inst.
    Nashville, Tennessee 37203, United States
  • Vanderbilt Medical Center
    Nashville, Tennessee 37232-7610, United States
  • The Netherlands Cancer Institute of Amsterdam
    Amsterdam, 1066 CX, Netherlands
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02174172
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 25, 2014
Start date
Aug 18, 2014
Primary completion
Nov 25, 2019
Completion
Nov 25, 2019
Last update
May 12, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Hoffmann-La Roche

Start the discussion